ReCor Medical snags CE mark for next-gen renal denervation

Now that Boston Scientific ($BSX) has purchased Vessix Vascular, California's ReCor Medical is the only privately held company with a CE marked renal denervation device. Now the company is upping the ante, getting European approval for a second generation of its ultrasound-powered Paradise. The new Paradise works faster than its predecessor thanks to an improved cooling technology, the company says, and ReCor remains the only player in the renal denervation space that uses ultrasound over radiofrequency to deaden nerves and reduce blood pressure. More

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.